B.Sc., Biology, California State University at Hayward Ph.D., Cell Biology, University of California at Los Angeles

Size: px

Start display at page:

Download "B.Sc., Biology, California State University at Hayward Ph.D., Cell Biology, University of California at Los Angeles"

Jeremy Stewart
6 years ago
Views:

Cecil Pickett President, Research & Development B.Sc., Biology, California State University at Hayward Ph.D., Cell Biology, University of California at Los Angeles Dr.

1 Cecil Pickett President, Research & Development B.Sc., Biology, California State University at Hayward Ph.D., Cell Biology, University of California at Los Angeles Dr. Pickett joined Biogen Idec in Prior to joining the company, he held several senior R&D positions, most recently as a Corporate Senior Vice President of Schering Plough Corp. & President of Schering-Plough Research Institute. In that capacity, Dr. Pickett helped bring several large and small molecule candidates into the Schering-Plough clinical development pipeline. Prior to joining Schering-Plough, he held several senior R&D positions at Merck & Co.

2 Al Sandrock Senior Vice President, Neurology Research & Development B.A., Human Biology, Stanford University M.D., Harvard Medical School Ph.D., Neurobiology, Harvard University Dr. Sandrock joined Biogen Idec in He is a board-certified specialist in Neurology and Electrodiagnostic Medicine, Assistant Clinical Professor of Neurology at Harvard Medical School, and Clinical Associate in Neurology at Massachusetts General Hospital in Boston. His contributions to the literature include journal articles on the identification of antigens that promote neurite growth and axonal regeneration, and the role of neuregulin at the neuromuscular junction.

Evan Beckman Senior Vice President, Immunology Research & Development A.B., Biochemistry, Princeton University M.D., University of Pennsylvania School of Medicine Dr.

3 Evan Beckman Senior Vice President, Immunology Research & Development A.B., Biochemistry, Princeton University M.D., University of Pennsylvania School of Medicine Dr. Beckman joined Biogen Idec in He leads an R&D portfolio of over 12 immunology based discovery projects and 11 clinical development programs in the areas of rheumatology, dermatology, gastroenterology and cardiopulmonary disease. Prior to joining the company, Dr. Beckman completed a clinical fellowship in rheumatology and laboratory immunology at Brigham and Women's Hospital and Harvard Medical School.

Greg Reyes Senior Vice President, Oncology Research & Development M.D., Ph.D., Johns Hopkins Dr. Reyes joined Biogen Idec in 2008.

4 Greg Reyes Senior Vice President, Oncology Research & Development M.D., Ph.D., Johns Hopkins Dr. Reyes joined Biogen Idec in With nearly 25 years of experience in the biotechnology and pharmaceutical industries, he has held senior leadership roles at companies including Pfizer, Schering-Plough and Cyclacel. His career has spanned virus discovery and characterization to drug discovery and development of small molecules and biologics. Dr. Reyes conducted his postdoctoral training at Stanford s University Hospital with Henry Kaplan, M.D., at the Cancer Biology Research Lab as a Damon Runyon Cancer Research fellow.

David Allsop Senior Regional Vice President, International B.S., Applied Chemistry, Coventry Polytechnic Mr. Allsop joined Biogen Idec in 1998 as head of the United Kingdom affiliate.

5 David Allsop Senior Regional Vice President, International B.S., Applied Chemistry, Coventry Polytechnic Mr. Allsop joined Biogen Idec in 1998 as head of the United Kingdom affiliate. Since then, he has held various international commercial positions within the company. Prior to joining Biogen Idec, he was with Johnson & Johnson in various commercial positions. He began his career as a Research Chemist.

Linda Burkly Distinguished Investigator, Molecular Discovery Ph.D., Immunology, Tufts University Sackler School of Biomedical Science Dr. Burkly joined Biogen Idec in 1985.

6 Linda Burkly Distinguished Investigator, Molecular Discovery Ph.D., Immunology, Tufts University Sackler School of Biomedical Science Dr. Burkly joined Biogen Idec in Her prior experience spans both discovery research and clinical stage development programs, and she has contributed to the discovery and/or advancement of multiple therapeutics, including a novel anti- CD4 mab-based HIV inhibitor (currently being developed by TaiMed, Taiwan), TYSABRI, and inhibitors of TNF superfamily ligands, including CD40L and TWEAK.

David Hagerty Vice President, Chief Medical Officer B.S., University of Notre Dame M.D., St. Louis University School of Medicine Dr. Hagerty joined Biogen Idec in 2006.

7 David Hagerty Vice President, Chief Medical Officer B.S., University of Notre Dame M.D., St. Louis University School of Medicine Dr. Hagerty joined Biogen Idec in Previous to Biogen Idec, he was Executive Director / Medical Lead at Bristol Myers Squibb where he focused on the development of two key immunology compounds. He also was a leader of the company s scientific licensing team, identifying and assessing opportunities that fit with disease area strategy.

Hari Hariharan Associate Director, Molecular Discovery D.V.M., University of Peradeniya, Sri Lanka Ph.D., University of Nebraska, Omaha Medical Center Dr. Hariharan joined Biogen Idec in 1991.

8 Hari Hariharan Associate Director, Molecular Discovery D.V.M., University of Peradeniya, Sri Lanka Ph.D., University of Nebraska, Omaha Medical Center Dr. Hariharan joined Biogen Idec in Since joining the company, he has worked on several oncology projects at different stages of discovery and development. His contributions include the proof-of-concept and mechanistic studies that led to the successful transition of rituximab, lumiliximab and galiximab into development for hematological malignancies.

Karen Lundgren Principal Scientist, Pharmacology B.A., Barnard College Ph.D., University of California, Irvine Post Doctoral Fellow, Cold Spring Harbor Laboratory Dr.

9 Karen Lundgren Principal Scientist, Pharmacology B.A., Barnard College Ph.D., University of California, Irvine Post Doctoral Fellow, Cold Spring Harbor Laboratory Dr. Lundgren joined Biogen Idec in 2004 as a Director of Pharmacology and Team Discovery Leader for the Hsp90 Project. Previously, she held various positions in research pharmacology at Corvas, Agouron Pharmaceuticals, Pfizer R&D, and Glaxo. Her research has included the discovery of small molecules and biologics targeted towards cell cycle, serine proteases and metabolic pathways for development in Oncology indications.

Tony Manning Vice President, Inflammation & Autoimmune Diseases Research Ph.D., BioChemistry, University of Otago, New Zealand Dr. Manning joined Biogen Idec in 2007.

10 Tony Manning Vice President, Inflammation & Autoimmune Diseases Research Ph.D., BioChemistry, University of Otago, New Zealand Dr. Manning joined Biogen Idec in Prior to joining the company, he was Vice President and Global Head of Inflammation, Autoimmunity and Transplantation Research at Roche. Previous to that, he held senior roles in research and development at Pharmacia and Signal Pharmaceuticals where he was President of Arthritis and Inflammation Research and Head of Pre-clinical Development, respectively.

11 Jennifer Michaelson Principal Scientist, Molecular Discovery A.B., Princeton University M.A. and Ph.D, Albert Einstein College of Medicine Dr. Michaelson joined Biogen Idec in Prior to joining the company, she conducted her post-doctoral fellowship in the laboratory of Philip Leder, M.D. in the Department of Genetics at Harvard Medical School.

Gilmore O Neill Senior Director, Experimental Neurology M.B., B.Ch., B.A.O., University College, Dublin, Ireland M. Med. Sci., Harvard University Dr. O Neill joined Biogen Idec in 2003.

12 Gilmore O Neill Senior Director, Experimental Neurology M.B., B.Ch., B.A.O., University College, Dublin, Ireland M. Med. Sci., Harvard University Dr. O Neill joined Biogen Idec in In addition, he is an instructor in neurology at Harvard Medical School and Director of the Leukodystrophy Service at Massachusetts General Hospital. Dr. O Neill s clinical interests lie in leukodystrophy, musculoskeletal diseases, and peripheral neuropathies, and his research interests lie in X-linked adrenoleukodystrophy (X-ALD) and the adrenomyeloneuropathy phenotype, and female penetrance of X-ALD.

Mike Panzara Vice President, Chief Medical Officer B.A., Biology, University of Pennsylvania M.D., Stanford University School of Medicine MPH, Harvard School of Public Health Dr.

13 Mike Panzara Vice President, Chief Medical Officer B.A., Biology, University of Pennsylvania M.D., Stanford University School of Medicine MPH, Harvard School of Public Health Dr. Panzara joined Biogen Idec in 2001 as the medical lead for TYSABRI studies. In that role, he oversaw the studies that led to the approval of the product, as well as the safety review and global approval in Dr. Panzara also holds appointments in the Department of Neurology at Massachusetts General Hospital and at Harvard Medical School as an Instructor in Neurology.

Robert Peters Director, Molecular & Cellular Biology B.S., Agriculture and Biological Engineering, Cornell University Ph.D., Biochemistry, Harvard University Dr. Peters joined Biogen Idec in 2000.

14 Robert Peters Director, Molecular & Cellular Biology B.S., Agriculture and Biological Engineering, Cornell University Ph.D., Biochemistry, Harvard University Dr. Peters joined Biogen Idec in His prior experience ranges across biotechnology, primarily focusing on the creation of novel Fc fusion proteins and characterizing their activity. He has been a leader for the company s Factor IX program since its inception. He is also the co-inventor of the monomeric Fc fusion that is being applied to the Factor VIII and IX programs.

15 Ken Rhodes Vice President, Discovery Neurobiology B.A., Psychology, Williams College Ph.D., Anatomy and Neurobiology, Boston University Dr. Rhodes joined Biogen Idec in 2007, after nearly five years as a Research Fellow and CNS Team Leader at Johnson & Johnson Pharmaceutical Research & Development, LLC. Dr. Rhodes spent 10 years in Neuroscience Discovery Research at Wyeth where he lead drug discovery activities in acute neurodegenerative disease, ion channels and transcriptional profiling. He has led drug discovery programs in the areas of Alzheimer s disease, multiple sclerosis, Parkinson s disease, epilepsy, and stroke and other CNS disorders.

Sha Mi Principal Investigator, Molecular Discovery Ph.D., Molecular and Cellular Biology, Rutgers University Dr. Mi joined Biogen Idec in 2000.

16 Sha Mi Principal Investigator, Molecular Discovery Ph.D., Molecular and Cellular Biology, Rutgers University Dr. Mi joined Biogen Idec in She received her postdoctoral training in the laboratory of Nobel Laureate Richard Roberts, Ph. D. at the Cold Spring Harbor Laboratory. At Biogen Idec, her current focus is to identify therapeutics for the treatment of demyelination disease such as multiple sclerosis. Her group was the first to identify a protein, LINGO-1, that blocks myelination repair in laboratory tissue culture and in animal disease models and whose inhibition may allow for remyelination and repair of damaged axons.

Art Taveras Vice President, Chemistry B.S., Chemistry, Rensselaer Polytechnic Institute M.S., Organic Chemistry, Rensselaer Polytechnic Institute Ph.D.

17 Art Taveras Vice President, Chemistry B.S., Chemistry, Rensselaer Polytechnic Institute M.S., Organic Chemistry, Rensselaer Polytechnic Institute Ph.D., Synthetic Organic Chemistry, Rensselaer Polytechnic Institute Dr. Taveras joined Biogen Idec in Prior to joining the company, he was Vice President, Global Drug Discovery & CMC Development at Alantos Pharmaceuticals. Previous to that, he held various positions of increasing responsibility in research and development at Schering-Plough, including the role of Director Band D-02/Research Fellow Drug Discovery.

Barry Ticho Vice President, Cardiology & Emerging Therapeutic Areas M.D. and Ph.D., University of Chicago Dr. Ticho joined Biogen Idec in 2001 in the company s cardiology research group.

18 Barry Ticho Vice President, Cardiology & Emerging Therapeutic Areas M.D. and Ph.D., University of Chicago Dr. Ticho joined Biogen Idec in 2001 in the company s cardiology research group. Prior to joining the company, he was Associate Director of Clinical Pharmacology at Merck & Co., where he designed and monitored phase 1 and 2 pharmacokinetic and proof of concept studies for pediatric gonadotropin antagonist, PGE antagonist, and protease inhibitor programs. A pediatric cardiologist by training, Dr. Ticho maintains a position as an Assistant in Pediatrics at Massachusetts General Hospital.

Speakers Title & Biography

Speakers Title & Biography Dr. Janice M. Soreth Deputy Director, FDA Europe Office/CDER, Liaison to EMA Dr. Soreth 20-year agency veteran with unparalleled experience, including serving as CDER's director